EGFR and head and neck squamous cell carcinoma: No clinical trials have been performed among HNSCC patients for the following drugs: canertinib (EGFR inhibitor); dactolisib, PF-04691502, apitolisib, and omipalisib (PI3K inhibitors); and refametinib, binimetinib, trametinib, and pimasertib (MEK inhibitors).